Trump announces trade deal with EU following months of negotiations
SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst expectations and provided weaker-than-expected guidance for 2025.
The company reported adjusted earnings per share of $0.45 for Q4, falling short of the $0.52 consensus estimate. Revenue came in at $1.11 billion, slightly above the $1.1 billion analysts were expecting and up 8% YoY.
For the full year 2024, DexCom’s revenue grew 11% to $4.03 billion. U.S. revenue increased 10% while international revenue rose 15%.
Looking ahead, DexCom forecast 2025 revenue of approximately $4.6 billion, below the $4.61 billion consensus. The company expects a non-GAAP gross profit margin of 64-65% and a non-GAAP operating margin of about 21%.
"In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA," said Kevin Sayer, DexCom’s chairman, president and CEO. "As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.